RNA
$13.13+0.44 (+3.47%)
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision...
Recent News
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion
SNV4818 is an oral treatment being evaluated in an early and mid-stage study for breast cancer and other advanced solid tumors.
Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline
Novartis (SWX:NOVN) issues US$11b in US dollar bonds to fund its planned US$12b acquisition of Avidity Biosciences. The bond financing highlights the company’s focus on expanding its medicines portfolio through large-scale M&A. Separately, Novartis signs a licensing agreement with Unnatural Products for macrocyclic peptide therapeutics targeting cardiovascular disease. Both moves add new platforms and modalities to the Novartis pipeline beyond recent product approvals and corporate...
Novartis acquisition spin-off pioneers RNA therapeutics for the heart
The newly launched Atrium Therapeutics will focus on precision RNA therapeutics for rare, genetic cardiomyopathies.
Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal
Seven-tranche bond sale helps repay bridge loan tied to Avidity acquisition, amid $26 billion investment-grade issuance surge.
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State